BeNeLuxBelgiumNetherlandsLuxembourg

ActoGeniX: 20 million euros round

16.03.2007

Ghent – The Belgian biopharma start-up ActoGeniX has closed a series A financing round in the volume of a20 million. The transaction was co-led by the two renowned VC investors Life Sciences Partners and GIMV. ActoGeniX has already announced a first closing of this transaction, raising a11.5 million. The company, which was founded in summer 2006, is developing a portfolio of novel therapeutic products addressing major diseases with unmet medical need, including gastrointestinal diseases, auto-immunity, allergy and metabolic diseases. ActoGeniX’ initial focus is on inflammatory bowel diseases and its lead product AG011 has been successfully tested in a clinical trial with Crohn’s disease patients. The company’s technology provides a solution to deliver active biologicals locally in the gastrointestinal tract, leading to a direct effect on target receptors present in the gut.

BeNeLuxBelgiumNetherlandsLuxembourg

03.11.2010

Leiden – Overshadowed by contamination problems at Crucell N.V.’s vaccine plant in South Korea, pharmaceutical and healthcare giant Johnson & Johnson has continued the purchase of 82.5 % of the Dutch biotechnology vaccine maker...

BeNeLuxBelgiumNetherlandsLuxembourg

27.10.2010

Leuven – Researchers from Leuven University have demonstrated that German Merck’s monoclonal EGF receptor (EGFR) antagonist cetuximab (Erbitux) offers benefits to patients with metastatic colorectal cancer even when they carry...

BeNeLuxBelgiumNetherlandsLuxembourg

26.10.2010

Brussels - Healthcare institutions from Europe have launched a new pilotprocess testing multi-stakeholder consultations in early-stage drugdevelopment. The purpose of the project is to reach an agreement about whatconstitutes a...

BeNeLuxBelgiumNetherlandsLuxembourg

08.10.2010

Leiden/New Brunswick – Johnson & Johnson will acquire all outstanding shares of Dutch Crucell N.V. for approximately EUR1.75 billion in a recommended cash tender offer, according to the companies. J&J said that it expects to...

BeNeLuxBelgiumNetherlandsLuxembourg

20.09.2010

Leiden/News Brunswick - Johnson & Johnson is set to bag all outstanding shares of Dutch protein and vaccine developer Crucell N.V. Currently Johnson & Johnson, through an affiliate, holds approx. 17.9% of the shares of Crucell...

BeNeLuxBelgiumNetherlandsLuxembourg

03.09.2010

Rotterdam/Leuven – Cartilage replacement specialist TiGenix N.V. has entered into an agreement with its academic partners KU Leuven and Ghent University, the Dutch company Therosteon and a consortium of investors for the...

BeNeLuxBelgiumNetherlandsLuxembourg

02.09.2010

Groningen – Researchers from the University of Groningen have identified a new mechanism that enables cancer cells to resist platinum-based chemotherapy. In resistant cancer stem cells of patients with testicular cancer, the team...

Displaying results 71 to 80 out of 304

< Previous 71-80 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/7/article/actogenix-20-million-euros-round.html

Events

All Events

Stock list

All quotes

TOP

  • THERAMETRICS0.09 CHF12.50%
  • PAION2.99 EUR11.15%
  • CO.DON3.00 EUR5.63%

FLOP

  • 4SC1.09 EUR-6.03%
  • STRATEC BIOMEDICAL39.80 EUR-3.40%
  • ADDEX3.22 CHF-3.30%

TOP

  • SANTHERA91.65 CHF43.0%
  • CO.DON3.00 EUR26.1%
  • PAION2.99 EUR20.1%

FLOP

  • EVOTEC3.07 EUR-18.1%
  • 4SC1.09 EUR-18.0%
  • MEDIGENE4.06 EUR-14.0%

TOP

  • SANTHERA91.65 CHF1987.7%
  • CO.DON3.00 EUR244.8%
  • PAION2.99 EUR187.5%

FLOP

  • CYTOS0.24 CHF-94.0%
  • 4SC1.09 EUR-43.2%
  • MERCK KGAA67.58 EUR-41.3%

No liability assumed, Date: 15.09.2014


Current issue

All issues

Product of the week

Products